ft 27 jul 93 schere ms drug approv us first effect treatment multipl sclerosi ms approv use us world largest market food drug administr approv first anywher world drug call betaseron develop schere german bioscienc group first treat underli diseas exist therapi reduc symptom ill progress schere share rose dm15 50 dm850 medicin biotechnolog deriv product recommend fda advisori committe march treatment relaps remit multipl sclerosi submit june last year demonstr fda belief urgent need product drug prove difficult manufactur commerci quantiti made us chiron corp californian base compani receiv 15 per cent sale chiron share rose dollar 3 1 2 dollar 68 1 2 schere build european product facil plan start clinic trial shortli diseas affect mani 350 000 peopl us 125 000 150 000 suffer form multipl sclerosi europ 3m multipl sclerosi suffer 65 per cent patient women betaseron cost dollar 5 000 dollar 7 000 per patient per year schere estim treatment multipl sclerosi current cost dollar 20 000 year german group predict annual sale dm750m end decad approv given basi trial 300 multipl sclerosi patient show betaseron doubl time attack well lessen sever side effect includ fever flu like symptom